ARIC Manuscript Proposal # 1153 PC Reviewed: 04_/_18_/06 Status: __A__ Priority: __2__ SC Reviewed: __04/19/06_ Status: __A__ Priority: __2__ 1.a. Full Title: Circulating caveolin-1 levels and prostate cancer incidence b. Abbreviated Title (Length 26 characters): Caveolin-1 and prostate cancer

[1]  C. Ren,et al.  Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. , 2001, Cancer research.

[2]  M. Ittmann,et al.  Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. , 2001, Cancer research.

[3]  T Hayakawa,et al.  Invasion activating caveolin-1 mutation in human scirrhous breast cancers. , 2001, Cancer research.

[4]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[5]  T. Wheeler,et al.  Elevated caveolin-1 levels in African-American versus white-American prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  T. Timme,et al.  Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis , 2000, Oncogene.

[7]  L. Truong,et al.  Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. , 1999, Cancer research.

[8]  J. Cerhan,et al.  Prostate Cancer Trends 1973-1995, SEER Program National Cancer Institute. , 1999 .

[9]  A. Neugut,et al.  Association between coronary heart disease and cancers of the breast, prostate, and colon. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  T. Timme,et al.  Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells , 1998, Nature Medicine.

[11]  M. Kattan,et al.  Elevated expression of caveolin is associated with prostate and breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  C. Fielding,et al.  Intracellular cholesterol transport. , 1997, Journal of lipid research.

[13]  A. Bist,et al.  Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Bostwick,et al.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.

[15]  L. Donehower,et al.  Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. , 1995, Oncogene.

[16]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[17]  D. Grignon,et al.  Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.

[18]  A. Zietman,et al.  Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. , 1994, Urology.

[19]  A. Partin,et al.  Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. , 1994, The Journal of urology.

[20]  D McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[21]  C R Weinberg,et al.  The design and analysis of case-control studies with biased sampling. , 1990, Biometrics.

[22]  W. Whitmore.  Natural history of low-stage prostatic cancer and the impact of early detection. , 1990, The Urologic clinics of North America.

[23]  J H Lubin,et al.  Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.

[24]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .